Leap Therapeutics Inc
LPTX2.050USD
0.0000.00%
終値 02/06, 16:00（ET）15分遅れの株価
84.95M時価総額
損失額直近12ヶ月PER
詳細情報 Leap Therapeutics Inc 企業名
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways. The Company’s lead clinical stage drug candidate is sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. The Company is developing DKN-01 in a clinical trial in patients with colorectal cancer and has also conducted clinical trials in patients with gastric/gastroesophageal junction cancer and endometrial cancer patients. The Company also has a preclinical program to develop a proprietary monoclonal antibody known as FL-501. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
Leap Therapeutics Incの企業情報
企業コードLPTX
会社名Cypherpunk Technologies Inc
上場日Jan 24, 2017
最高経営責任者「CEO」Onsi (Douglas E)
従業員数52
証券種類Ordinary Share
決算期末Jan 24
本社所在地47 Thorndike Street
都市CAMBRIDGE
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号02142
電話番号16172524343
ウェブサイトhttps://www.leaptx.com/
企業コードLPTX
上場日Jan 24, 2017
最高経営責任者「CEO」Onsi (Douglas E)
Leap Therapeutics Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
141.58K
+712.00%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Director
Director
23.76K
+712.00%
Ms. Christine Granfield
Ms. Christine Granfield
Vice President, Head - Regulatory Affairs and Quality
Vice President, Head - Regulatory Affairs and Quality
15.90K
+15896.00%
Dr. Jason Baum, Ph.D.
Dr. Jason Baum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
15.90K
+15896.00%
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
214.00
--
Dr. Thomas Dietz, Ph.D.
Dr. Thomas Dietz, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. William W. Li, M.D.
Dr. William W. Li, M.D.
Independent Director
Independent Director
--
--
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Nissim Mashiach
Mr. Nissim Mashiach
Independent Director
Independent Director
--
--
Mr. Mark O'Mahony
Mr. Mark O'Mahony
Chief Manufacturing Officer
Chief Manufacturing Officer
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
141.58K
+712.00%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Director
Director
23.76K
+712.00%
Ms. Christine Granfield
Ms. Christine Granfield
Vice President, Head - Regulatory Affairs and Quality
Vice President, Head - Regulatory Affairs and Quality
15.90K
+15896.00%
Dr. Jason Baum, Ph.D.
Dr. Jason Baum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
15.90K
+15896.00%
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
214.00
--
Dr. Thomas Dietz, Ph.D.
Dr. Thomas Dietz, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
収益内訳
会社から関連データがまだ開示されていません。
会社から関連データがまだ開示されていません。
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Mon, Jan 5
更新時刻: Mon, Jan 5
株主統計
種類
株主統計
株主統計
比率
Winklevoss Capital Management, LLC
14.62%
Severns (Sean Michael)
10.59%
Gilead Sciences Inc
9.39%
The Vanguard Group, Inc.
3.75%
BofA Global Research (US)
2.55%
他の
59.09%
株主統計
株主統計
比率
Winklevoss Capital Management, LLC
14.62%
Severns (Sean Michael)
10.59%
Gilead Sciences Inc
9.39%
The Vanguard Group, Inc.
3.75%
BofA Global Research (US)
2.55%
他の
59.09%
種類
株主統計
比率
Family Office
14.62%
Corporation
11.53%
Individual Investor
11.07%
Investment Advisor
6.53%
Investment Advisor/Hedge Fund
3.10%
Research Firm
2.88%
Venture Capital
1.25%
Hedge Fund
0.35%
Bank and Trust
0.01%
他の
48.65%
機関投資家保有株
更新時刻: Thu, Jan 1
更新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
109
9.04M
15.96%
-11.00M
2025Q3
109
9.06M
16.46%
-11.77M
2025Q2
120
18.70M
45.12%
-8.55M
2025Q1
140
18.85M
45.62%
-6.95M
2024Q4
134
21.35M
55.72%
-2.16M
2024Q3
140
20.83M
54.42%
+2.16M
2024Q2
141
20.87M
54.74%
+4.28M
2024Q1
149
9.36M
39.74%
-1.79M
2023Q4
154
7.72M
34.00%
-3.79M
2023Q3
169
9.36M
44.45%
-1.96M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Winklevoss Capital Management, LLC
8.28M
14.62%
+8.28M
--
Oct 24, 2025
Severns (Sean Michael)
6.00M
10.59%
+6.00M
--
Nov 12, 2025
Gilead Sciences Inc
5.32M
9.39%
--
--
Oct 24, 2025
The Vanguard Group, Inc.
1.16M
2.05%
--
--
Sep 30, 2025
BofA Global Research (US)
1.44M
2.55%
+1.44M
+451295.63%
Sep 30, 2025
Acadian Asset Management LLC
1.24M
2.18%
--
--
Sep 30, 2025
Beigene Ltd
1.22M
2.15%
+1.22M
--
Oct 31, 2024
Simplify Asset Management Inc
975.61K
1.72%
+118.25K
+13.79%
Sep 30, 2025
HealthCare Ventures LLC
676.32K
1.19%
-20.91K
-3.00%
Oct 24, 2025
Geode Capital Management, L.L.C.
312.19K
0.55%
--
--
Sep 30, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
Simplify Health Care ETF
0.37%
iShares Micro-Cap ETF
0%
Dimensional US Core Equity 1 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Avantis US Small Cap Equity ETF
0%
Simplify Health Care ETF
比率0.37%
iShares Micro-Cap ETF
比率0%
Dimensional US Core Equity 1 ETF
比率0%
DFA Dimensional US Sustainability Core 1 ETF
比率0%
Avantis US Small Cap Equity ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
日付
配当落ち日
種類
比率
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
